This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Merck files reply to dismiss Humana's amended US antitrust claims over Zetia

( April 30, 2025, 22:31 GMT | Official Statement) -- MLex Summary: Merck filed a reply in support of dismissing Humana’s US antitrust claims accusing it of entering into an illegal pay-for-delay agreement, which kept a generic version of the cholesterol drug Zetia out of the market. Merck said Humana’s third amended complaint does not fill the gaps the court identified, as it still fails to allege that any relevant person was involved in or aware of the studies that would have caused some relevant patents to be rejected, that anyone acted with intent to deceive the Patent and Trademark Office, or that that the studies were material to patentability.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections